Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Varex Imaging Corporation (VREX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded Nasdaq issuer. Varex designs and manufactures X-ray imaging components and systems for medical, industrial, and security applications, and its filings offer detailed insight into how this business is reflected in its financial statements, risk factors, and governance disclosures.
Through this page, users can review Varex’s periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which present segment information for the Medical and Industrial businesses, revenue composition, gross margin, operating expenses including research and development, and details on capital structure items like long-term debt and convertible notes. These filings also contain management’s discussion and analysis and other disclosures that complement the high-level figures in press releases.
Current reports on Form 8-K document specific material events. For example, a recent 8-K furnished an earnings press release titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” while another 8-K described a transition agreement with the company’s Senior Vice President, Chief Legal Officer, and Corporate Secretary, outlining continued service, compensation, and equity vesting terms. Such filings help investors track both financial performance and key governance changes.
On Stock Titan, VREX filings are updated as they are made available through EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly understand topics such as segment performance, non-GAAP reconciliations, debt and liquidity, and executive arrangements. Users can also review ownership and insider activity through forms that report transactions by officers and directors, providing an additional perspective on Varex Imaging Corporation’s regulatory record.
Varex Imaging Corp executive Andrew Hartmann, SVP and GM, Detectors, reported equity award transactions in the company’s common stock. On 12/10/2025, restricted stock units vested and converted into 4,664 and 7,935 shares of common stock, with each unit converting one-for-one into a share. To satisfy tax withholding from this vesting, 3,636 shares were withheld at a price of $11.7 per share. After these transactions, he directly owned 36,182 common shares.
Hartmann also continues to hold stock-based incentives through restricted stock units. Units granted on December 10, 2023 vested 50% on December 10, 2025, with the remaining 50% scheduled to vest on December 10, 2027, and he held 7,936 restricted stock units following the reported transactions. In addition, he received a new grant of 26,041 restricted stock units on December 10, 2025, and held 26,401 restricted stock units afterward, scheduled to vest 50% on December 10, 2027 and 50% on December 10, 2029, with shares delivered on each vesting date.
Varex Imaging Corp President and CEO, who is also a director, reported equity award activity in company stock dated 12/10/2025. Previously granted restricted stock units (RSUs) converted into 26,652 and 47,613 shares of common stock as they vested, and 32,566 shares were withheld at a price of $11.7 to satisfy tax withholding obligations related to this vesting. After these transactions, the reporting person directly holds 231,892 shares of common stock.
On the same date, the officer received a new grant of 156,250 RSUs, which are scheduled to vest 50% on December 10, 2027 and 50% on December 10, 2029. Earlier RSU grants from December 10, 2021 and December 10, 2023 have already partially vested, with remaining portions scheduled to vest on December 10, 2027. Each RSU converts into one share of common stock upon vesting and delivery.
Varex Imaging Corp reported that its Chief Legal Officer received an equity award of 17,094 restricted stock units, each converting into one share of common stock. The award is reported as a Form 4 transaction dated December 10, 2025.
These restricted stock units are scheduled to vest in two equal installments, with 50% vesting on December 10, 2027 and the remaining 50% on December 10, 2029. On each vesting date, the underlying common shares will be delivered to the officer, providing long-term stock-based compensation tied to the company’s future performance.
Varex Imaging Corp’s chief human resources officer, Karen L. Aranki, reported equity award activity dated December 10, 2025. She acquired 6,665 shares of common stock upon the vesting of restricted stock units, which convert into common stock on a one-for-one basis. To cover tax withholding arising from this vesting, 1,923 shares were withheld and disposed of at a price of $11.7 per share, leaving her with 4,919 shares of common stock held directly afterward.
On the derivative side, 6,665 restricted stock units were settled into common stock, and she retained 6,666 restricted stock units from a grant originally made on December 10, 2023, which is scheduled to vest further on December 10, 2027. She also received a new grant of 21,875 restricted stock units on December 10, 2025, set to vest 50% on December 10, 2027 and 50% on December 10, 2029, with vested shares to be delivered on each vesting date.
Varex Imaging Corp's Chief Financial Officer reported multiple equity transactions in company stock. On 12/10/2025, restricted stock units converted into 7,063 and 13,966 shares of common stock, consistent with the one-for-one RSU terms. To cover tax obligations, 5,227 shares were disposed of at $11.7 per share, leaving 106,891 shares of common stock directly owned.
The report also shows a new grant of 58,333 restricted stock units, scheduled to vest 50% on December 10, 2027 and 50% on December 10, 2029, along with earlier RSU awards that continue to vest on their original schedules.
Varex Imaging Corporation (VREX) filed its annual report describing a global business focused on X-ray tubes, flat panel and photon counting detectors, software and related components used in medical, security and industrial inspection systems. The company operates two segments, Medical and Industrial, and works mainly with large OEM customers. As of April 4, 2025, non-affiliate market value was about $339.3 million, and as of November 11, 2025 there were 41.7 million common shares outstanding. Varex highlights revenue concentration, with its top five customers providing about 40% of 2025 revenue and Canon alone about 18%. The report also emphasizes extensive global regulation, trade and tariff exposure, especially in China, and notes MOFCOM investigations into imported CT X-ray tubes that affect roughly 10% of total revenue.
Varex Imaging Corporation (VREX) filed a current report to announce that it has released a press release with its preliminary operating results for the twelve months ended October 3, 2025. The press release, titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” is furnished as Exhibit 99.1 to the report and provides details on the company’s fourth quarter and full fiscal year 2025 performance. The company specifies that this information is being furnished under the securities laws rather than formally filed, which affects how it may be used in other regulatory documents.
Varex Imaging (VREX) insider filing: The company’s Chief Legal Officer filed an initial ownership report on Form 3. The filing states no securities are beneficially owned and lists an amount of 0 shares. The date of the event requiring the statement is 10/06/2025. This is a routine disclosure establishing insider reporting status.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting ownership of 1,992,611 shares of Varex Imaging Corp common stock, representing 4.8% of the outstanding class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership of the shares while acknowledging it may possess voting and/or investment power as adviser. Of the reported shares, 1,951,986 shares are listed as sole voting power and 1,992,611 as sole dispositive power. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Insider sale by Varex Imaging Corp officer under a pre-established plan. Karen L. Aranki, Chief Human Resources Officer and a company officer, reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share. After the transaction she beneficially owned 177 shares. The filing states the sales were effected pursuant to a 10b5-1 trading plan adopted June 17, 2025, indicating these trades followed an established written arrangement rather than ad hoc decisions. The Form 4 is signed and dated 09/22/2025.